924P - Abiraterone in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and MDV3100: a multicentre study

Date 29 September 2012
Event ESMO Congress 2012
Session Poster presentation I
Topics Anti-Cancer Agents & Biologic Therapy
Prostate Cancer
Presenter Diletta Bianchini
Authors D. Bianchini1, Y. Loriot2, E. Ileana2, S. Sandhu1, C. Pezaro1, L. Albiges2, G. Attard3, K. Fizazi4, J.S. De Bono5, C. Massard6
  • 1Prostate Targeted Therapy Group/ Ddu, Royal Marsden Hospital, SM25PT - Sutton/UK
  • 2Medical Oncology, Institut de cancérologie Gustave Roussy, 94800 - Villejuif/FR
  • 3Section Of Molecular Carcinogenesis, Royal Marsden Hospital, SM25PT - Sutton/UK
  • 4Department Of Medical Oncology, Institute Gustave Roussy, FR-94805 - Villejuif/FR
  • 5Royal Marsden Hospital, SM25PT - Sutton/UK
  • 6Sitep, Institute Gustave Roussy, FR-94805 - Villejuif/FR



Androgen receptor signalling remains critically important in metastatic castration resistant prostate cancer (mCRPC) as confirmed by recent Phase III trials showing a survival advantage for abiraterone acetate and MDV3100. These novel inhibitors of androgen biosynthesis and androgen receptor function are anticipated to be broadly utilized in the near future. The antitumor activity of abiraterone in patients pre-treated with MDV3100 is as yet unknown.


We investigated the activity of abiraterone acetate in patients with mCRPC who had progressed following treatment with docetaxel and MDV3100. Clinical data were retrospectively analysed for prostate-specific antigen (PSA) response, clinical benefit and progression-free survival (PFS). All patients received abiraterone 1000 mg/day plus prednisone 10mg/day.


Thirty-nine patients [median age 70 years: range 52-84, median baseline PSA 238 ng/mL range: 2-3000, metastatic sites: bone disease in 38 patients (97%), lymph nodes in 15 patients (38%) and visceral disease in 10 patients (26%)] were included in the analyses. Three patients (8%) attained a PSA response, defined as a decrease of >50% in PSA, confirmed after ≥ 4 weeks. A further six patients (15%) had a 30% PSA decline. The median PFS was 2.7 months (95% CI: 2.2 -3.9). Six out of 26 evaluable patients (23%) had a symptomatic response on pain score and decrease of analgesic consumption. Treatment was well-tolerated. One patient required discontinuation of abiraterone due to oedema and hypokalemia.


This study indicates that abiraterone has antitumor activity in patients with mCRPC pretreated with docetaxel and MDV3100. Further prospective evaluation of these agents administered in combination is now warranted (Richards J et al, Cancer Research 2012).


C. Pezaro: All authors are ICR employees. The ICR has a commercial interest in Abiraterone,

G. Attard: All authors are ICR employees. The ICR has a commercial interest in Abiraterone.

K. Fizazi: PI and advisory board for Jansen and Medivation,

J.S. de Bono: All authors are ICR employees. The ICR has a commercial interest in Abiraterone. JS de Bono has served as a paid consultant for J&J, Sanofi-Aventis, Medivation, Astellas, AstraZeneca, Dendreon, Genentech, Pfizer, GSK.

All other authors have declared no conflicts of interest.